INTRODUCTION
Even though new developments in clinical research on breast cancer (BC) have provided clinicians with a set of important diagnostic tools, there is still an urgent need for further, more sensitive staging techniques. Recent studies have shown that quantitative and qualitative analyses of circulating tumour cells (CTC) may provide prognostic information in BC [1, 2] . Attempts to isolate CTC in peripheral blood (PB) date back to more than 100 years [3] . Sandberg et al. isolated CTC from BC patients using centrifugation and fibrinogen to aggregate erythrocytes [4] . Notably, Hsieh et al. reported that the absolute count of CTC may be related to an aggressive course of disease in BC patients [5] . First attempts to isolate CTC through immunomagnetic separation were made by Berois et al using a CK-19 on BC cell lines [6] . This technique was recently successfully used by Hardingham et al. in patients with gastrointestinal neoplasias [7] . Combining immunomagnectic separation and real-time-PCR (RT-PCR), this group could positively correlate the presence of CTC in PB with shorter disease-free intervals.
Gene profile analyses of certain putative genetic markers may lead to sensitive and specific CTC detection and may enable an improvement in the outcome prediction [8] [9] [10] [11] [12] [13] . In fact, PCR and RT-PCR can be applied to perform expression analyses of immunomagnectically isolated CTC. In a previous study we analysed the CTC of 63 BC patients in various disease stages and identified the genes ga733.2, muc-1, mgb1 and spdef as putative markers for CTC detection. Based upon our previous data, in this study we performed correlation analyses between the detected gene expression levels and the known clinical staging of breast cancer. Furthermore, we compared the gene expression data with the detected Ca15-3 serum levels. Increased serum levels of the tumour marker Ca 15-3 have been associated with advanced disease and poor outcome in several studies [14, 15] .
MATERIALS AND METHODS
Our study population consisted of 63 BC patients and 14 healthy controls. 50 patients with first diagnosed disease (FD) and 13 patients with metastatic disease (MD) in various disease stages were enrolled. All patients provided written informed consent. After peripheral venous blood sampling, CTC were separated using an immunomagnetic method (Adnagen Breast Cancer Select Kit) according to the instructions of the manufacturer (Adnagen). Cell lysates underwent mRNA isolation and reverse transcription following the manufacturer's instructions (Promega). Subsequently, mPCR for the genes ga733.2 and muc-1 and RT-PCR for the genes mgb1 and spdef were performed. The resulting gene profiles were then compared with tumour stage according to the TNM grading system and tumour stage of the American Joint Committee on Cancer (AJCC) [16] 
DISCUSSION
Haematological dissemination of malignant cells is a prerequisite to distant organ metastases in many cancer entities [21] [22] [23] [24] . Yet, several studies suggest that only a minority of tumour cells have the ability to invade and metastasize [17] [18] [19] . Therefore, it is crucial to investigate which genes ultimately facilitate tissue invasion and disease progression. Here, we propose an association between a certain set of genes (ga733.2, muc-1, mgb1 and spdef) and advanced tumour stages in BC. Notably, the studied gene signature exposed a significant correlation with stage levels IIIa or higher. Herein, muc-1 expression significantly correlated with nodal and distant metastases, and hence higher staging levels. In line with these results, it has been recently shown that a muc-1-induced tumourigenesis gene signature could predict diseasefree and overall survival in patients with breast and lung cancer [20] .
All investigated genes and gene profiles were significantly correlated with Ca 15-3 positivity. Since elevated levels of this tumour marker have been shown to predict the outcome in BC, the gene signature we analyzed is likely to hold prognostic relevance.
The present investigation poses several questions: First, since the analyses was not performed in a prospective manner, it is impossible to determine whether the detected gene profiles in patients with late disease might also be present in early stages of the disease. Second, it remains to be studied whether CTC exhibit a daily or hourly fluctuation in the gene expression levels. This could lead to false negative results in the proposed method.
In summary, our data indicate a notable correlation between the studied genes (ga733.2, muc-1, mgb1 and spdef) and advanced disease in BC. Accordingly, the studied genes might play a role in the process of metastases formation. However, prospective studies in a larger patient population are needed to further validate the proposed hypothesis. 
